Currently, serum levels of patients with HHM are assessed using RIA to detect PTHrP, this assessment would be a potential factor in determining Apo2L/TRAIL sensitivity of patients with PTHrP positive tumours. This evidence concerns the gene TNFSF10 and neoplasm.